Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thursday, May 1st, 2025. I would now like to turn the conference over to El Nilem. Please go ahead. Good morning. I'm Christine Lindenboom, Chief Corporate Communications Officer at El Nilem. With me today are Vaughn Greenstreet, Chief Executive Officer, Tolga Tangular, Chief Commercial Officer, Pushbull Garg, Chief Medical Officer, and Jeff Fulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website investors.alnylam.com slash events. During today's call, as outlined in slide two, Yvonne will offer introductory remarks and provide some general context. Tolga will provide an update on our global commercial progress, Pushkal will review pipeline updates and clinical progress, and Jeff will review our financials and guidance, followed by a summary of our upcoming milestones before we open the call to your questions. I would like to remind you that this call will contain remarks concerning Alnylam's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the safe proper provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent periodic report on file with the SEC. In addition, any forward-looking statements represent our views only as of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'd like to turn the call over to Yvonne. Yvonne? Thanks, Christine, and thank ...